| Code | CSB-RA723415MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to IPH5301, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E contributes to immunosuppression by inhibiting T cell and NK cell activity while promoting regulatory T cell function. Elevated NT5E expression has been associated with multiple cancers, including triple-negative breast cancer, ovarian cancer, melanoma, and colorectal cancer, where it correlates with poor prognosis and immune evasion.
IPH5301 is a therapeutic antibody developed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression and enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating NT5E-dependent mechanisms in cancer immunity, adenosine signaling pathways, and immune checkpoint regulation. It supports studies exploring combination immunotherapy strategies and tumor microenvironment modulation.
There are currently no reviews for this product.